# Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

> **NCT03785652** · PHASE1 · COMPLETED · sponsor: **Luye Pharma Group Ltd.** · enrollment: 260 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** LY03005 extended-release tablets 40 mg
- **DRUG:** LY03005 extended-release tablets 80 mg group
- **DRUG:** LY03005 extended-release tablets 120 mg group
- **DRUG:** LY03005 extended-release tablets 160 mg group
- **DRUG:** Placebo group

## Key facts

- **NCT ID:** NCT03785652
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-09
- **Primary completion:** 2015-10-31
- **Final completion:** 2015-10-31
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2018-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03785652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03785652, "Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03785652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*